SetPoint Medical Appoints Ankit Shah to Lead Commercialization and
Marketing

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint
Medical, a clinical-stage biomedical technology company developing
bioelectronic therapy for chronic inflammatory diseases, announced today
the appointment of Ankit Shah as Senior Director of Commercialization
and Marketing. Mr. Shah has more than a decade of experience developing
and commercializing innovative medical technology.

Mr. Shah will oversee SetPoint’s efforts to commercialize its
proprietary bioelectronic device as the company advances their
bioelectronic medicine approach to treat autoimmune inflammatory
diseases including rheumatoid arthritis, Crohn’s disease and multiple
sclerosis.

“SetPoint is pleased to welcome Ankit. Ankit’s experience and drive will
help in the development and implementation of our commercialization
strategy,” said Anthony
Arnold, Chief Executive Officer of SetPoint Medical. “Ankit can help
us advance this new approach for treating inflammatory diseases through
the approval and reimbursement processes to ultimately expand treatment
options for patients suffering from some very debilitating conditions.”

Prior to joining SetPoint, Mr. Shah was the Senior Director of Marketing
and Business Development at Intersect ENT (NASDAQ: XENT). He joined
Intersect ENT as a founding member of the commercialization team and led
their product marketing and physician education initiatives. He also
held positions at Medtronic, SV Health Investors and was awarded a
fellowship grant from the Food and Drug Administration. He holds a B.S.
and M.S. in Biomedical Engineering from Marquette University and an
M.B.A. in Health Care Management from The Wharton School at the
University of Pennsylvania.

About SetPoint Medical

SetPoint
Medical is a privately held biomedical technology company dedicated
to treating patients with debilitating inflammatory diseases using
bioelectronic therapy. SetPoint’s approach is intended to offer patients
and providers a treatment alternative
for rheumatoid arthritis (RA) and other chronic inflammatory diseases
with less risk and cost than drug therapy.

SetPoint is developing a novel bioelectronic medicine platform that
stimulates the vagus nerve to activate the body’s natural Inflammatory
Reflex, which is intended to produce a potent systemic anti-inflammatory
effect. The company has published positive results from a first-in-human
proof-of-concept trial in rheumatoid arthritis in Proceedings of the
National Academy of Sciences (PNAS) and presented positive results at
the American College of Rheumatology meeting. Current investors
in the company include Morgenthaler Ventures, New Enterprise Associates
(NEA), Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential
Venture Capital Limited and Boston Scientific. For more information,
visit www.setpointmedical.com.